Loading
BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
Anti-apoptotic protein known as inhibitor of apoptosis (IAP) which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Unlike most IAPs, does not contain a RING domain and it is not a RING-type E3 ligase. Instead acts as a dual E2/E3 enzyme that combines ubiquitin conjugating (E2) and ubiquitin ligase (E3) activities in a single polypeptide.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.83, genetic association 0.19, somatic mutation 0.55). IntOGen calls it a driver in 21 cohorts (6 activating, 14 loss-of-function), covering Anal Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma and others.
In plain words · BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
Anti-apoptotic protein known as inhibitor of apoptosis (IAP) which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase.
No product in this corpus aims at BIRC6 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA BIRC6: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 10 nTPM); high antibody staining in 10 normal tissues; highest cancer staining breast cancer (4 of 11 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Breast cancer (all types), Renal cell carcinoma, Endometrial cancer, Anal cancer (squamous cell carcinoma), Colorectal cancer, Hepatocellular carcinoma and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9NR09; CIViC gene BIRC6; IntOGen BIRC6; Human Protein Atlas BIRC6 tissue; Open Targets ENSG00000115760 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Chen et al, Biochem. Biophys. Res. Commun, 1999, "A human IAP-family gene, apollon, expressed in human brain cancer cells". Source.
Sources: HGNC HGNC:13516 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NR09 (protein name, function text, keywords and locations (REST API)); CIViC gene BIRC6 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000115760 (association with cancer (MONDO_0004992) 0.63; (GraphQL API, CC0)); IntOGen BIRC6 (driver in 21 cohorts (Act 6, LoF 14); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Anti-apoptotic protein known as inhibitor of apoptosis (IAP) which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Unlike most IAPs, does not contain a RING domain and it is not a RING-type E3 ligase. Instead acts as a dual E2/E3 enzyme that combines ubiquitin conjugating (E2) and ubiquitin ligase (E3) activities in a single polypeptide. Ubiquitination is mediated by a non-canonical E1 ubiquitin activating enzyme UBA6. Ubiquitinates CASP3, CASP7 and CASP9 and inhibits their caspase activity; also ubiquitinates their procaspases but to a weaker extent. Ubiquitinates pro-apoptotic factors DIABLO/SMAC and HTRA2. Location: Golgi apparatus, trans-Golgi network membrane; Endosome; Cytoplasm, cytoskeleton, spindle pole; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome (UniProt). Locus 2p22.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (granulocytes 10 nTPM).
Medium: Appendix, Cerebellum, Cerebral cortex, Endometrium, Epididymis, Heart muscle, Hippocampus, Kidney.
Medium only: carcinoid, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"BIRC6" OR ABSTRACT:"BIRC6" OR TITLE:"baculoviral IAP repeat containing 6" OR ABSTRACT:"baculoviral IAP repeat containing 6" OR TITLE:"Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6" OR ABSTRACT:"Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6" OR TITLE:"BRUCE" OR ABSTRACT:"BRUCE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BIRC6, not a curated reading list.
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, IntOGen, Breast cancer (all types).
Shares Anal cancer (squamous cell carcinoma), IntOGen, Open Targets Platform.
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, Colorectal cancer.
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, Colorectal cancer.
Shares Anal cancer (squamous cell carcinoma), Head and neck squamous cell carcinoma.
Shares Anal cancer (squamous cell carcinoma), Colorectal cancer.
Shares Anal cancer (squamous cell carcinoma), Hepatocellular carcinoma, CIViC, IntOGen.
Shares Anal cancer (squamous cell carcinoma), Head and neck squamous cell carcinoma, Breast cancer (all types), Colorectal cancer.